The principal methods of providing renal replacement therapy (RRT) are peritoneal dialysis (PD), intermittent haemodialysis (IHD) and continuous renal replacement therapy (CRRT). Each method has advantages and limitations depending upon the patient status and disease process. IHD is readily available, uncomplicated and rapidly removes a solute or volume load. However, in the critically ill, dialysis-associated hypotension may adversely affect remaining renal function. 1 PD is inexpensive, widely available and does not cause hypotension but unfortunately is inefficient in removing large volumes of fluid or solute. It is contraindicated in the critically ill because increases in intraabdominal volume may cause diaphragmatic splinting, hindering weaning from artificial ventilation. CRRT allows control of uraemia and clearance of solute with greater cardiovascular stability, 2 though it is more expensive than intermittent techniques 3 and is not universally available. Continuous (rather than intermittent) techniques facilitate the management of ICU patients receiving parenteral nutrition or multiple i.v. infusions and may allow end-organ perfusion to be maintained more effectively. 4 In the intensive care unit, continuous veno-venous haemofiltration (CVVH) or continuous veno-venous haemodiafiltration (CVVHDF) are becoming the accepted standard of care.
Development of RRT
Thomas Graham, a Scottish chemist, first described a simple 'hoop' dialyser using a parchment septum in 1861. In 1913, John Abel developed the first dialysis system to be tested on animals. In 1924, Georg Haas first dialysed a human subject with acute renal failure, but the patient died because of the low efficiency of the dialyser. A major problem during early research was that the anticoagulant hirudin (a thrombin-specific inhibitor obtained from the salivary glands of the medical leech) was unsafe. Heparin was not discovered until 1922 and was only used for systemic anticoagulation in the 1940s. Modern dialysis began in 1945 when Willem Kolff enabled the first patient to survive acute renal failure using haemodialysis. In the mid-1950s, Teflon and Silastic catheters were developed, allowing permanent intravascular access. In the 1960s, PD became more popular, with the Tenchkhoff catheter allowing permanent intraperitoneal access rather than repeated abdominal wall puncture. Also in the 1960s, the first long-term treatments of chronic renal failure began and an American patient, Clyde Shields, survived for 11 yr while requiring haemodialysis. More efficient hollow-fibre dialysers were introduced during the same decade and subsequent mass production allowed reduced cost. Nevertheless, the process remained so expensive that in the USA anonymous committees decided who should be treated. In 1977, Kramer first described the use of CRRT to treat diuretic-unresponsive fluid overload. In the UK, CRRT has now virtually replaced IHD in the critical care setting.
Principles of haemodialysis and haemofiltration
The aims of RRT are solute and water removal, and correction of electrolyte abnormalities and acid-base disturbance. Two processes occur during RRT that result in the transfer of solutes or fluid across a semipermeable membrane: diffusion and convection.
Diffusion
Diffusion is the spontaneous migration of substances from regions where their concentrations are high to regions where their concentrations are lower. This redistribution occurs because of random motion of the chemical species of the substance. The rate of diffusion is proportional to the concentration gradient. Thus, while molecules continuously flow both into and out of all regions, the net
Key points
Continuous renal replacement therapy (CRRT) techniques are the method of choice for renal replacement in UK Intensive care units.
CRRT ensures solute and volume removal in haemodynamically stable conditions.
The inherent stability of CRRT may avoid the renal ischaemia caused by hypotension associated with intermittent haemodialysis (IHD).
The major risk of CRRT is bleeding secondary to circuit anticoagulation.
High volume haemofiltration (HVHF) may have a role in the management of sepsis via removal of 'middle molecules'.
flow is from regions of higher concentration to regions of lower concentration. In solutions, when the liquid solvent passes through a membrane but the solute (dissolved solid) is retained, the process is called osmosis. Diffusion of a solute across a membrane is called dialysis, especially when some solutes pass but others are retained. The process was described by Thomas Graham, who termed the substance that remained within the membrane a colloid and the substance that diffused a crystalloid. During haemodialysis, diffusive transport is driven by the solute concentration gradients that exist between blood and dialysate. The mass transfer of solute is dependent on its rate of diffusion, determined by the characteristics of the solute (size, charge, protein binding), the dialysis membrane (type, porosity, thickness, surface area), the rate of delivery of solute and the concentration of the dialysate. This is the principle process occurring during haemodialysis. The electrolyte solution (dialysate) runs in the opposite direction (countercurrent) to blood flow separated by a semipermeable membrane. Substances with a mass <20 kDa move along a concentration gradient into the dialysate fluid.
Convection
Convective transport, or solvent drag, occurs when a solute molecule is swept through a membrane by a moving stream of ultrafiltrate. Ultrafiltration is produced by creating a positive pressure in the blood compartment of the dialyser and is facilitated by creating a negative pressure in the dialysate compartment. The resulting transmembrane pressure is the driving force for ultrafiltration (analogous to the glomerulus of the kidney). Convective transport is independent of any solute concentration gradients that might be present across the membrane. The porosity of the membrane is a major determinant of which solutes are removed but only the direction and force of transmembrane fluid flux determine the amount of convective transport. Ultrafiltration is the process by which fluid is removed during haemofiltration, enabling correction of fluid overload and making room for administration of drugs and nutrition. The hydrostatic pressure in the blood compartment, and thus the transmembrane pressure, is dependent on the rate of blood flow to the membrane. In a spontaneous ultrafiltration system based on convective clearance, measures that maximize blood flow rate will maximize ultrafiltrate production and solute clearance. Equally, measures that increase the negative pressure in the ultrafiltrate compartment will also increase ultrafiltration, as will measures that decrease the oncotic pressure of plasma (e.g. pre-dilution, the administration of replacement fluid before the filter). The relationship between transmembrane pressure and oncotic pressure will determine the filtration fraction (i.e. the fraction of plasma water that is removed from blood during haemofiltration). The optimal filtration fraction for patients with a haematocrit of approximately 30% is 20-25%. Too high a filtration fraction leads to excessive haemoconcentration at the filter outlet, which causes blood clotting at the filter.
During haemodialysis, solute movement across the dialysis membrane from blood to dialysate is the result of diffusive transport. During haemofiltration, as no dialysate is used, diffusive transport cannot occur and solute transport is entirely dependent on convective transport. Thus, solute removal from the blood occurs more slowly with haemofiltration. These two modes of solute transport may occur simultaneously (haemodiafiltration) and overall clearance of a solute is equal to the sum of its diffusive and convective clearance. For any given dialyser, this will depend on blood and dialysate flow rates, the ultrafiltration rate and the concentration of solute in the blood and dialysate.
RRT membranes
There are two types of RRT membranes: cellulose-based and synthetic. Cellulose-based membranes have a low permeability coefficient to water (low-flux) and are used for dialysis. Synthetic membranes have a high permeability coefficient to water (high-flux), with high sieving coefficients for solutes in a wide range of molecular weights, and are much more appropriate for convective treatments (haemofiltration), though also suitable for haemodialysis and haemodiafiltration in the appropriate circuit. Synthetic haemofilters allow transfer of solutes with a mass <20 kDa (e.g. urea, creatinine, uric acid, ions, IL-6, endotoxin, heparin, pesticides, ammonia and most drugs unbound to plasma proteins) and cause less damage to platelets and white cells. Cellulose membranes activate inflammatory cascades and are considered less suitable in critical illness. There is no evidence that one filter type is superior to another in terms of outcome. 5 
Vascular access
Renal replacement therapies require dedicated vascular access (10-14 Fr gauge catheter). Modern double-lumen catheters avoid the multiple blood vessel punctures previously necessary to site separate catheters for blood flow away from and back to the patient. Two methods are possible: arterio-venous and venovenous. Arterio-venous RRT has greater vascular morbidity and depends on an adequate arterial blood pressure to drive blood flow, and so has largely been replaced by veno-venous RRT. For veno-venous access, a single large vein is cannulated percutaneously with a double-lumen catheter using the Seldinger technique. The right or left internal jugular veins are usually preferred as the subclavian vein may become stenosed during chronic use and is incompressible in the event of haemorrhage. Coagulopathic patients are more safely managed with a femoral catheter because the femoral vein is easily compressible. All catheters have a lumen that functions as the 'arterial' outflow limb of the circuit and a second lumen which functions as the 'venous' inflow limb of the circuit. The 'arterial' port removes blood from holes in the side of the catheter and blood is 
RRT circuits
An RRT system consists of an extracorporeal blood circuit, a filtrate circuit and, for CVVH, a replacement fluid circuit. Veno-venous RRT utilizes an 'occlusive' roller pump in the prefilter line segment, to circulate blood through the extracorporeal circuit.
In CVVH (Fig. 1) , production of a transmembrane pressure gradient across the haemofilter results in convective clearance of solute with filtered fluid. The resulting filtration rate varies between 0 and 30% of the blood flow rate. Further increases would result in greater haemoconcentration and shorten haemofilter life. Systems are capable of generating a blood flow of 700 ml min À1 ; transmembrane pressures produced at these flow rates allow ultrafiltration rates of 2 litre h À1 . Ultrafiltrate production rates are usually 20-35 ml kg À1 h
À1
. A calculated proportion of the ultrafiltrate is replaced with replacement fluid to achieve the desired overall fluid balance. In patients with fluid overload or cardiopulmonary dysfunction, a portion of the ultrafiltrate volume is not replaced, resulting in negative fluid balance.
IHD (Fig. 2) depends on diffusive solute clearance occurring because of the countercurrent flow of dialysate fluid through the haemofilter. The blood flow rate within the circuit is higher and high dialysate flows produce large filtrate volumes. Unlike CVVH, no replacement fluid is required as rapid solute removal is achieved with less total fluid loss from the patient.
CVVHDF is similar to CVVH but with the addition of a countercurrent dialysate fluid flow through the haemofilter. This allows both convective and diffusive flow to occur in order to increase solute clearance rates further.
Anticoagulation
All forms of RRT activate the clotting cascade by exposing blood to contact with a non-biological surface. Filtration fraction is limited to 20-30% to limit haemoconcentration, but anticoagulants are also used to prolong filter life, while minimizing systemic anticoagulation. Heparin is most 
Drip chamber
Venous access (Blood flow=200-400 ml min -1 ) Fig. 2 Intermittent haemodialysis circuit. In IHD blood is pumped from the patient and arrives at the haemofilter via a similar circuit to CVVH. However, dialysate fluid is pumped through the haemofilter in a countercurrent direction in order to produce and maintain solute concentration gradients across the semipermeable membrane. Solute transfer occurs by diffusion as a result. , which inhibits platelet aggregation within the circuit. Prostacyclin is a potent vasodilator, sometimes reducing mean arterial pressure by 15 mm Hg or more. Low molecular weight heparin or citrate may also be used.
Replacement fluids
During haemofiltration, depending on the filter type, water and solutes up to a molecular mass of approximately 15-20 kDa are removed. Bicarbonate ions are freely filtered and metabolic acidosis occurs unless these ions are replaced or regenerated. Bicarbonate ions are not present in most replacement solutions for two main reasons. First, bicarbonate-containing mixtures have a short shelf-life because bicarbonate ions are converted to carbonates which dissociate, with resultant loss of CO 2 by diffusion through the container wall. Second, mixtures of bicarbonate and calcium lead to precipitation of calcium carbonate. Lactate is an acceptable bicarbonate substitute, provided that it is efficiently metabolized to CO 2 and water, generating new bicarbonate ions via the TCA cycle in the liver. The normally functioning liver can metabolize 100 mmol h À1 of lactate, compensating for bicarbonate losses during filtration. In the critically ill, this may not occur because of hepatic dysfunction or a high lactate load resulting from lactic acidosis (serum lactate >5 mmol litre À1 ); therefore, either a bicarbonatebuffered replacement fluid (prepared locally without calcium or magnesium) or lactate-free replacement fluid (where sodium bicarbonate is infused independently of the circuit) is used. The replacement fluid may either be added to the circuit before the haemofilter (pre-dilution) or mixed with the blood in the venous drip chamber (post-dilution). Pre-dilution may reduce the incidence of filter clotting and hence anticoagulation requirements, but reduces clearance of solute; therefore, post-dilution is more commonly used.
Intermittent vs continuous therapy
There are no definitive randomized controlled trials showing reduced mortality in critical illness with a given type of RRT; a systematic review of RRT modality found no difference in mortality or dialysis-dependence among survivors. 6 PD has many disadvantages in the critical care setting, including poor solute clearance, a significant incidence of peritonitis, refractory hyperkalaemia, poor glucose control and impairment of weaning from mechanical ventilation because of increases in intra-abdominal volume.
Debate has focused on whether continuous techniques are preferable to IHD in critical care. Continuous techniques have many practical advantages providing a physiological, safe and progressive removal of fluid and solute. The major disadvantage of IHD in the critically ill is the risk of hypotension, particularly in those with cardiovascular instability and perfusion deficits secondary to multi-organ failure. Hypotension may further reduce end-organ perfusion, particularly in the kidneys that may have lost pressure-flow autoregulation. Conversely, mean arterial pressure and systemic vascular resistance tend to increase during CRRT because continuous slow ultrafiltration allows compensatory fluid shifts from the interstitium to the intravascular space to maintain preload. This preserves organ perfusion, avoiding ischaemia. IHD may also lead to fluid overload between treatments, which cannot be tolerated by some patients. CRRT allows continuous fluid removal, reducing extravascular water and facilitating parenteral nutrition. Further advantages include better control of uraemia, body cooling (decreasing tachycardia, basal metabolic rate and oxygen requirements) and avoidance of dysequilibrium syndrome (by maintaining normal intracranial and cerebral perfusion pressures).
Although IHD is superior for rapid solute removal, its intermittent nature means the total daily solute clearance is less than with continuous therapies. CRRT controls peak urea concentrations and also dialysable intoxications better than IHD despite being less efficient. Plasma concentrations of drugs with a large volume of distribution will be rapidly reduced with IHD but may increase again once dialysis ceases, whereas CRRT allows continued gradual drug elimination. CRRT membranes are more porous than HD membranes and are more efficient at removing middle-sized molecules, such as inflammatory mediators. A recent retrospective study showed that recovery of renal function after acute renal failure is significantly more common with CRRT than with IHD 7 and the majority of both retrospective and prospective studies show a trend towards reduced mortality with CRRT rather than IHD. 8 On balance, current evidence suggests that only patients with uncomplicated ARF should receive IHD, whereas critically ill patients should receive CRRT. IHD is slightly more economical (approximately 6% cheaper) than CRRT and may be used safely in the recovery phase of critical illness when cardiovascular instability resolves (Table 1) .
Initiating and maintaining RRT
The timing of initiation of RRT in the absence of emergency indications (Table 2) is controversial. There are no definitive randomized, controlled trials demonstrating optimum starting points for RRT. Conservative measures to control renal failure may be used initially (e.g. diuretics, bicarbonate administration, fluid restriction). A more aggressive approach is to initiate CRRT early, aiming to limit physiological derangement before Renal replacement therapies in critical care severe complications develop. By virtue of its inherent haemodynamic stability, early CRRT has a low associated morbidity, even in the critically ill; treatment can begin when plasma urea is 20-30 mmol litre À1 , or lower if further deterioration in renal function is inevitable. A study using early RRT in patients with acute renal failure following polytrauma showed a mortality decrease of 50%. 9 Intensity of RRT is also controversial but it appears that, in critical care patients, more is better. In a recent study where patients with ARF were randomized to receive ultrafiltration volumes of 20, 35 or 45 ml kg À1 h
À1
, patients with more intense RRT had significantly lower mortality rates, although there was no further difference in survival between the higher two ultrafiltration intensities. 10 Most centres aim for a maintenance urea of <25-30 mmol litre
. In critical illness, the dialysis dose above which no further mortality improvement is seen remains unclear but the ultrafiltration rate should probably be at least 35 ml kg À1 h À1 .
Potential use in sepsis
Many patients with ARF have multi-organ dysfunction secondary to severe sepsis or the systemic inflammatory response syndrome (SIRS). Most mediators involved in the inflammatory response are water soluble middle-sized molecular weight compounds, such as tumour necrosis factor (TNF), interleukins (IL-1, IL-6, IL-8), platelet activating factor (PAF) and complement. The highly porous synthetic membranes used for convective filtration in CVVH lend themselves to elimination of such compounds through filtration and adsorption. However, conventional ultrafiltration rates of 20 ml kg À1 h À1 do not reduce plasma mediator concentrations or improve outcome in ARF secondary to sepsis. 11 High volume haemofiltration (HVHF), producing ultrafiltration volumes of more than 75 litre day À1 , may be required to produce significant reductions in plasma mediator concentrations because of their very high generation rate. Improvements in both cardiovascular stability and outcome have been shown in animal models. 12 Some human studies have suggested improvement in cardiovascular function, vasopressor requirement and outcome using HVHF. 13 
Conclusion
It is likely that the role of CRRT in critical care will continue to expand. More aggressive RRT, with earlier intervention and more intensive filtration, has already shown improvements in outcome. Further investigation is required to fully establish the promising role of RRT in the management of sepsis. 
